Does Melanotan II cross the blood-brain barrier?

Direct BBB passage is variable across peptide compounds and is rarely the dominant mechanism. Melanotan II produces CNS effects through some combination of: direct BBB transport (at low efficiency for most peptides), vagal-afferent gut-brain axis signalling, and effects on cerebral vasculature where the barrier is locally compromised. The CNS effects observed in research consistently appear at peripheral doses, supporting the indirect-access framework.

Best route for cognitive applications — injection or intranasal?

For most Melanotan II cognitive use cases, the route that delivers the compound closest to its target site of action is preferred. Intranasal delivery via the olfactory pathway is the standard for direct CNS access where available.

Does Melanotan II cross the blood-brain barrier?

Direct BBB passage is variable across peptide compounds and is rarely the dominant mechanism. Melanotan II produces CNS effects through some combination of: direct BBB transport (at low efficiency for most peptides), vagal-afferent gut-brain axis signalling, and effects on cerebral vasculature where the barrier is locally compromised. The CNS effects observed in research consistently appear at peripheral doses, supporting the indirect-access framework.

Best route for cognitive applications — injection or intranasal?

For most Melanotan II cognitive use cases, the route that delivers the compound closest to its target site of action is preferred. Intranasal delivery via the olfactory pathway is the standard for direct CNS access where available.

Is Melanotan II appropriate alongside SSRIs or other psychiatric medications?

Melanotan II's pharmacology is generally additive rather than competitive with most psychiatric medications, but the combined modulation of monoamine systems warrants supervision. Users on SSRIs, SNRIs, lithium, or atypical antipsychotics should consult their prescriber before adding Melanotan II to the regimen.

Best route for cognitive applications — injection or intranasal?

For most Melanotan II cognitive use cases, the route that delivers the compound closest to its target site of action is preferred. Intranasal delivery via the olfactory pathway is the standard for direct CNS access where available.

Should I cycle Melanotan II?

Standard cycle for Melanotan II is 8–12 weeks of daily during loading, then 1-2x weekly 0.25-0.5 mg dosing via subq/intranasal, followed by a 4 week complete off-period. The off-period is calibrated to Melanotan II's ~30 min half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

What route should I use for Melanotan II?

Melanotan II is delivered by subq/intranasal. The intranasal route is preferred for compounds targeting the central nervous system because it bypasses the BBB via the olfactory pathway. The choice depends on target system and convenience.

What is the evidence base for Melanotan II?

Melanotan II's evidence base sits at mechanistic + off-label. The references on this page summarise 1 primary publication supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The cognitive / neurological interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

Is Melanotan II safe during pregnancy or breastfeeding?

Melanotan II, like most non-approved peptide therapeutics, does not have safety data supporting use during pregnancy or lactation. The default position is contraindication during pregnancy, lactation, and active conception, with discontinuation at least 2–3 cycles before planned conception. Approved indications (where they exist) may have specific guidance — verify with the prescribing physician.

Home/ Compounds/ Melanotan II

Melanotan II

Neuroprotection

Neurology research on Melanotan II examines whether this cyclic α-msh analogue produces measurable CNS effects beyond peripheral activity. The cognitive case rests on three convergent threads: non-selective melanocortin receptor agonist (mc1, mc3, mc4, mc5) mc1r drives pigmentation; mc4r drives appetite suppression and sexual response; mc3r/5r contribute to energy expenditure and sebaceous secretion. cyclic structure resists enzymatic degradation.; downstream consequences for monoamine and neurotrophic signalling; and reduction of chronic neuroinflammation. Melanotan II is dosed at 0.25-0.5 mg daily during loading, then 1-2x weekly via subq/intranasal in cognitive-focused protocols, with the ~30 min pharmacokinetic profile shaping receptor occupancy timing.

Cognitive / Neurological Applications

NeurogenesisPost-TBI RecoveryHPA Axis ModulationGut-Brain AxisStroke Recovery

Key Takeaways

Cognitive lens: Melanotan II acts as a restorative compound rather than a stimulant for cognitive endpoints.
CNS access pattern: BBB transport plus vagal-afferent gut-brain signalling and cerebral vascular effects.
Mechanism: Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5).
Neuro dose: 0.25-0.5 mg daily during loading, then 1-2x weekly via subq/intranasal; cognitive effects accumulate across 4-8 weeks.
Cognitive stack partners: Semax, Selank, Semax + Selank Blend.

Cognitive / Neurological Mechanism

Three pathways shape Melanotan II's cognitive profile: Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5). MC1R drives pigmentation; MC4R drives appetite suppression and sexual response; MC3R/5R contribute to energy expenditure and sebaceous secretion. Cyclic structure resists enzymatic degradation. Each subsection below covers one - CNS access mechanisms, neurotrophic and monoamine effects, and the inflammation-and-recovery layer that often produces the most subjectively reported cognitive shifts.

Cerebral perfusion and the structural cognitive substrate

Cognitive function depends on adequate cerebral perfusion, intact endothelial signalling, and a low chronic-inflammatory tone in the brain parenchyma. Melanotan II, with its Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5) MC1R drives pigmentation; MC4R drives appetite suppression and sexual response; MC3R/5R contribute to energy expenditure and sebaceous secretion. Cyclic structure resists enzymatic degradation. mechanism, contributes to this substrate rather than producing acute stimulant-like activation. Across the cognitive applications outlined below, what users describe is restoration of baseline rather than amplification above it. The ~30 min pharmacokinetic profile supports this restorative rather than stimulant phenotype.

Inflammation and neurological recovery

One of the most replicated effects across compounds in Melanotan II's class (Cyclic α-MSH analogue) is reduction of inflammatory cytokines (TNF-α, IL-1β, IL-6) in tissues including the central nervous system. For users whose cognitive complaints track with chronic low-grade neuroinflammation — long-COVID, post-viral cognitive fog, post-concussion lingering symptoms, chronic stress — this anti-inflammatory layer is often the most operationally relevant mechanism. Melanotan II's contribution operates on the same axis at 0.25-0.5 mg per dose.

Pharmacokinetics and cognitive dose timing

The ~30 min half-life of Melanotan II via subq/intranasal administration sets the timing window for cognitive effects. At 0.25-0.5 mg daily during loading, then 1-2x weekly, receptor occupancy curves and CNS exposure align with the typical multi-week onset profile reported by cognitive-focused users. The standard daily during loading, then 1-2x weekly dosing pattern is calibrated to maintain therapeutic exposure without continuous saturation, preserving the natural rhythm of the targeted system.

Cognitive / Neurological Applications

Cognitive Recovery

Where Melanotan II is used for cognitive recovery, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.

Stroke Recovery

Stroke Recovery is one of the more-reported subjective benefits of Melanotan II across cognitive-focused user cohorts. The mechanism is plausible given the compound's neurotrophic and anti-inflammatory profile; the effect size depends substantially on baseline status.

Mood Stabilisation

For mood stabilisation, Melanotan II is most-relevant in users whose cognitive complaints track with chronic neuroinflammation or post-injury recovery. Effect size is modest but consistent across well-tolerated dose ranges, with typical response window of 4–8 weeks.

BDNF Support

Where Melanotan II is used for bdnf support, the dosing window is typically 4–8 weeks with re-evaluation at the end of cycle. Stacking with selank or semax is common in this use case; pure-isolated dosing is also viable for first-cycle users.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	0.25-0.5 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1.25-0.5 mg	4–6 weeks initial cycle
Neuroprotection focus	SubQ	0.25-0.5 mg	Daily during loading, then 1-2x weekly
Maintenance phase	SubQ	1.25-0.5 mg	Ongoing with periodic pauses

Dose timing for Melanotan II is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Melanotan II stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from the cognitive neuroscience community.

Melanotan II + Semax: Elevates BDNF and NGF in hippocampus and cortex. Pairs naturally with Melanotan II's mechanism in cognitive / neurological protocols.
Melanotan II + Selank: Modulates GABA-A receptor systems indirectly. Pairs naturally with Melanotan II's mechanism in cognitive / neurological protocols.
Melanotan II + Semax + Selank Blend: Semax raises BDNF and modulates dopamine systems; Selank stabilises GABAergic and serotonergic tone. Pairs naturally with Melanotan II's mechanism in cognitive / neurological protocols.
Melanotan II + DSIP: Mechanism remains incompletely characterised. Pairs naturally with Melanotan II's mechanism in cognitive / neurological protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved Research: Mechanistic + off-label

Nausea (especially early), spontaneous erections in men, marked appetite suppression, hyperpigmentation. Watch new moles closely. Avoid in melanoma history.

Lens-specific safety considerations for cognitive / neurological use of Melanotan II: Nausea (especially early), spontaneous erections in men, marked appetite suppression, hyperpigmentation. Watch new moles closely. Avoid in melanoma history. Additional cognitive / neurological monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Melanotan analogues and melanocortin receptor pharmacology

PMID 1429592

Melanotan II vs Related Peptides

Compound	Profile	Onset	Best For
Melanotan II	Cyclic α-MSH analogue	~30 min	Neuroprotection
Semax	ACTH-derived nootropic heptapeptide	CNS effect hours; plasma minutes	A Russian-developed analogue of ACTH(4-10) extended with a Pro-Gly-Pro tail for proteolytic stability — a clinically used nootropic and stroke recovery agent
Selank	Tuftsin-derived heptapeptide anxiolytic	CNS effect lasts hours; plasma short	A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder
DSIP	Neuropeptide (sleep)	~7 min plasma; CNS effects longer	A short neuropeptide isolated from sleeping rabbits in 1977, of interest for its modulation of delta-wave sleep and stress resilience
Pinealon	Khavinson tripeptide (pineal-derived)	Short plasma; durable tissue effects	A Khavinson pineal-derived tripeptide of glutamate-aspartate-arginine, studied for neuroprotection and cognitive function in aged and ischemic models

Frequently Asked Questions

Is Melanotan II a true nootropic?

Not in the caffeine-or-modafinil sense. Melanotan II does not acutely sharpen attention or working memory in healthy users. Its cognitive value is restorative — supporting recovery from neurological injury, reducing chronic neuroinflammation, and stabilising the upstream systems that cognitive function depends on.

Cognitive side effects to watch for?

Reported issues are uncommon in animal and limited human data but include mild sedation, vivid dreams, transient mood lability in the first week, and infrequent headache. There are no large-scale human safety trials. Discontinue if mood symptoms are concerning and re-evaluate.

Can Melanotan II be stacked with other nootropics?

Yes, and it is commonly paired. The cleanest pairings are with compounds on complementary pathways — anxiolytic (selank), neurotrophic (semax), sleep-architecture (DSIP), or anti-inflammatory (LL-37) — rather than with other compounds engaging the same pathway.

How long until I notice cognitive effects?

Mood and gut-related symptoms often shift within 5–14 days. Cognitive recovery and inflammation-related changes accumulate across 4–8 weeks. Stimulant-like 'feel it today' effects are not the typical Melanotan II profile; the compound is restorative rather than acutely activating.

What is the regulatory status of Melanotan II?

Melanotan II regulatory status: Unapproved in the United States; WADA status not on prohibited list; research level mechanistic + off-label. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For cognitive and neurological use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What does Melanotan II stack well with?

For cognitive / neurological protocols, Melanotan II pairs with compounds on complementary pathways: Semax, Selank, Semax + Selank Blend. These pairings are selected because they engage independent receptor systems from Melanotan II's primary mechanism (Non-selective melanocortin receptor agonist (MC1, MC3, MC4, MC5)), producing additive or synergistic effects rather than receptor competition.

Clinical Protocol

Start a Melanotan II Protocol

Alukard provides physician-supervised cognitive protocols with GMP-certified Melanotan II and GMP-certified compounds and comprehensive neurological assessments.

Get Protocol

Quick Facts

Molecular weight: 1024 Da
Sequence length: 7 aa
Half-life: ~30 min
WADA: Not on prohibited list
FDA: Unapproved
Research: Mechanistic + off-label

Stack Partners

Semax

Selank

Semax + Selank Blend

DSIP

LL-37

Research Note

All cognitive / neurological applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Melanotan II unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised cognitive protocols

Start Your Cognitive / Neurological Protocol for Melanotan II

Alukard provides physician-supervised cognitive protocols with GMP-certified compounds and comprehensive neurological assessments.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised